NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

QLGN

Qualigen Therapeutics Inc

Jul 01 • 04:00PM ET

3.32

Dollar change -0.09
Percentage change -2.72	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX NVAX INO CERS VXRT ALT AIM PDSB ADMA

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-33.17	Insider Own	6.96%	Shs Outstand	0.74M	Perf Week	-7.00%
Market Cap	2.44M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.69M	Perf Month	-11.94%
Enterprise Value	6.99M	PEG	-	EPS next Q	-	Inst Own	1.17%	Short Float	4.03%	Perf Quarter	-8.79%
Income	-6.25M	P/S	-	EPS this Y	-	Inst Trans	-17.65%	Short Ratio	0.65	Perf Half Y	-22.79%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-183.32%	Short Interest	0.03M	Perf YTD	-21.14%
Book/sh	-4.12	P/C	2.09	EPS next 5Y	-	ROE	-2140.54%	52W High	29.43 -88.72%	Perf Year	-62.72%
Cash/sh	1.59	P/FCF	-	EPS past 3/5Y	61.60% 79.32%	ROIC	-233.17%	52W Low	2.85 16.49%	Perf 3Y	-98.82%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.41% 6.08%	Perf 5Y	-99.86%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	73.76%	Oper. Margin	-	ATR (14)	0.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.33	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	37.30	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.33	EPS Q/Q	95.01%	SMA20	-9.15%	Beta	0.03	Target Price	250.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-9.54%	Rel Volume	0.22	Prev Close	3.41
Employees	-	LT Debt/Eq	0.00	Earnings	-	SMA200	-26.18%	Avg Volume	42.70K	Price	3.32
IPO	Jun 24, 2015	Option/Short	No / Yes	EPS/Sales Surpr.	21.74% -100.00%	Trades		Volume	9,586	Change	-2.72%

May-19-25 05:25PM	Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q (GlobeNewswire)
May-01-25 04:20PM	Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K (GlobeNewswire)
Apr-01-25 08:00AM	Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme (GlobeNewswire)
Jan-28-25 08:00AM	Qualigen to participate in next funding round for NanoSynex (GlobeNewswire) -21.42%
Dec-05-24 09:00AM	Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement (GlobeNewswire)
05:00PM	Loading…
Nov-25-24 05:00PM	Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (GlobeNewswire) -6.50%
Nov-19-24 09:00AM	Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares (GlobeNewswire) +6.04%
Nov-01-24 09:00AM	Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 (GlobeNewswire)
Sep-26-24 05:10PM	Qualigen Therapeutics, Inc. Announces management changes. (GlobeNewswire)
Sep-20-24 09:00AM	Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel (GlobeNewswire)
Sep-06-24 05:00PM	Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (GlobeNewswire)
04:30PM	Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering (GlobeNewswire)
Sep-05-24 09:00AM	Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering (GlobeNewswire) -10.68%
Aug-16-24 09:53PM	QLGN Stock Earnings: Qualigen Therapeutics Reported Results for Q2 2024 (InvestorPlace) +11.48%
Jul-15-24 08:19AM	Why Is Qualigen Therapeutics (QLGN) Stock Down 22% Today? (InvestorPlace) -10.92%
07:35AM	Loading…
07:35AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jul-12-24 11:56AM	Mizuho Just Raised Its Price Target on Tesla (TSLA) Stock (InvestorPlace) +111.45%
11:15AM	Why Is Qualigen (QLGN) Stock Up 141% Today? (InvestorPlace)
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jul-09-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) -20.79%
Jul-08-24 10:08AM	Boeing Pleads Guilty: Why BA Stock Is Up on Criminal Case News (InvestorPlace)
08:35AM	Why Is Qualigen Therapeutics (QLGN) Stock Down 12% Today? (InvestorPlace)
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jul-02-24 09:52PM	QLGN Stock Earnings: Qualigen Therapeutics Reported Results for Q1 2024 (InvestorPlace) +5.98%
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +18.58%
Jun-20-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -5.29%
Jun-03-24 10:53AM	QLGN Stock Earnings: Qualigen Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
May-30-24 04:00PM	Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination (GlobeNewswire)
Apr-16-24 07:00AM	Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft (GlobeNewswire) -6.28%
08:00AM	Loading…
Apr-10-24 08:00AM	Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Apr-09-24 08:00AM	Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Nov-14-23 04:30PM	Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 (GlobeNewswire)
Nov-07-23 08:30AM	Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors (GlobeNewswire)
Oct-23-23 08:30AM	Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer (GlobeNewswire)
Sep-27-23 08:30AM	Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 (GlobeNewswire)
Aug-30-23 07:09AM	QLGN: Receives U.S. FDA IND Clearance; Phase 1 Trial to Initiate 2H23 (Zacks)
Aug-17-23 08:30AM	Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors (GlobeNewswire)
Aug-15-23 08:30AM	Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023 (GlobeNewswire)
Aug-01-23 08:30AM	Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors (GlobeNewswire)
Jul-24-23 08:15AM	Qualigen Therapeutics Divests FastPack® Diagnostics Business (GlobeNewswire)
Jun-14-23 10:30AM	QLGN: Data for Pan-RAS Platform Presented at ASCO (Zacks Small Cap Research)
Jun-05-23 08:15AM	Poster Highlighting Qualigen Therapeutics Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire)
May-16-23 08:00AM	Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023 (GlobeNewswire)
May-12-23 07:20AM	QLGN: IND for QN-302 to be Submitted in Mid-2023 (Zacks Small Cap Research) -5.69%
May-02-23 04:30PM	Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +7.29% -5.98%
08:15AM	Qualigen Therapeutics Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire)
Apr-21-23 05:46PM	Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing (GlobeNewswire)
Apr-18-23 08:45AM	Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL (GlobeNewswire) -5.48%
07:30AM	Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL (GlobeNewswire)
Mar-21-23 08:35AM	Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office (GlobeNewswire) +16.33%
Mar-15-23 09:05AM	Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-09-23 08:30AM	Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference (GlobeNewswire)
Mar-08-23 08:05AM	Data on Potential Biomarker for Qualigen Therapeutics Lead Program QN-302 Published in Peer-Reviewed Journal Molecules (GlobeNewswire) -7.14%
Feb-01-23 09:05AM	Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders (GlobeNewswire) +10.85%
Jan-24-23 09:00AM	Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302 (GlobeNewswire)
Jan-23-23 09:02AM	Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications (GlobeNewswire)
Jan-10-23 09:00AM	Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer (GlobeNewswire) +5.51%
Jan-05-23 09:00AM	Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform (GlobeNewswire) +9.73%
Dec-12-22 08:30AM	Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire)
Dec-07-22 09:10AM	Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors (GlobeNewswire) -6.21%
Dec-01-22 07:11AM	QLGN: Encouraging Preclinical Data Presented for QN-302 and RAS Inhibitor (Zacks Small Cap Research) +20.20%
Nov-22-22 09:00AM	Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split (GlobeNewswire) -14.50%
Nov-17-22 06:12AM	Qualigen Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-15-22 07:30AM	Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-19-22 09:00AM	Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute (GlobeNewswire)
Oct-18-22 09:00AM	Qualigen Therapeutics to Present at LD Micro Main Event XV (GlobeNewswire)
Oct-06-22 08:00AM	Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium (GlobeNewswire) -10.06%
Sep-14-22 05:02PM	Qualigen Therapeutics Presents Data on QN-302 at AACRs Pancreatic Cancer Meeting (GlobeNewswire) -5.71%
Aug-25-22 06:45AM	QLGN: FastPack Sales Up 28% YoY (Zacks Small Cap Research)
Aug-18-22 09:15AM	Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board (GlobeNewswire)
Aug-16-22 07:30AM	Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-01-22 08:30AM	Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model (GlobeNewswire)
Jul-06-22 09:00AM	Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302 (GlobeNewswire)
Jun-14-22 09:00AM	Qualigen Therapeutics to Present at BIO International Convention (GlobeNewswire)
Jun-07-22 09:04AM	Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials (GlobeNewswire)
Jun-06-22 06:10AM	QLGN: Acquires Majority Stake in Israeli Diagnostics Technology Company NanoSynex (Zacks Small Cap Research)
Jun-02-22 09:00AM	Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex (GlobeNewswire) +5.36%
May-26-22 09:15AM	Qualigen Therapeutics Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting (GlobeNewswire)
May-20-22 09:15AM	Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-13-22 06:00AM	Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire) +7.65%
May-10-22 09:17AM	Qualigen Therapeutics Partner NanoSynex to Present Technology at BioMed Israel (GlobeNewswire)
May-03-22 02:24PM	Qualigen Takes Stake In NanoSynex To Gain Access To Next-Gen Diagnostic Platform (Benzinga)
09:17AM	Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex (GlobeNewswire)
Apr-29-22 09:15AM	Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President (GlobeNewswire)
Apr-18-22 06:25AM	QLGN: Secures Worldwide Rights to G4-Selective Cancer Therapeutics (Zacks Small Cap Research) -12.75%
Apr-12-22 10:15AM	Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference (GlobeNewswire) +52.06%
Apr-05-22 09:15AM	Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack® (GlobeNewswire)
Apr-01-22 08:00AM	Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results (GlobeNewswire)
Mar-30-22 09:15AM	Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302 (GlobeNewswire)
Mar-22-22 09:15AM	Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference (GlobeNewswire) +8.04%
Mar-15-22 09:15AM	Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program (GlobeNewswire)
Feb-22-22 09:15AM	Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders (GlobeNewswire)
Feb-15-22 09:15AM	Data from Qualigen Therapeutics Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference (GlobeNewswire)
Feb-01-22 09:15AM	Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302 (GlobeNewswire)
Jan-18-22 09:15AM	Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics (GlobeNewswire)
Dec-14-21 09:18AM	Qualigen Therapeutics Promotes Amy Broidrick to President (GlobeNewswire)
Dec-01-21 03:25PM	Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering (GlobeNewswire)
Nov-29-21 03:50PM	QUALIGEN THERAPEUTICS, INC. ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING (GlobeNewswire) -7.06%
Nov-22-21 10:23AM	QLGN: Revenues Increase 38% YoY (Zacks Small Cap Research) +25.62%

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QLGN

Qualigen Therapeutics Inc

Upgrade your FINVIZ experience